Skip to main content
. Author manuscript; available in PMC: 2021 Dec 23.
Published in final edited form as: J Pain Symptom Manage. 2021 Feb 20;62(3):e65–e74. doi: 10.1016/j.jpainsymman.2021.02.010

Table 2.

Effect of Receiving Targeted Therapy on Patient-Reported Outcomes Among Patients With Lung Cancer

Receiving Targeted Therapy N = 35 Mean, SE Without Targetable Mutations N = 119 Mean, SE P-value of Difference in Baseline Scores
Quality of life –FACT-G
Baseline 77.85, 2.42 77.18, 1.44 0.821
12 weeksa 83.01, 1.70 74.95, 1.79
24 weeksb 88.11, 2.26 78.05, 1.82
Symptom burden –LCS
Baseline 19.17, 0.41 19.81, 0.86 0.465
12 weeks 21.85, 0.95 19.53, 0.45
24 weeks 22.92, 0.87 19.60, 0.52
Depression–HADS-D
Baseline 4.94, 0.71 4.74, 0.39 0.806
12 weeks 4.09, 0.77 5.43, 0.43
24 weeks 2.70, 0.60 5.01, 0.45
Anxiety –HADS-A
Baseline 5.49, 0.74 6.01, 0.36 0.503
12 weeks 4.35, 0.66 5.17, 0.39
24 weeks 4.04, 0.66 4.97, 0.39
a

At 12 weeks, n=32 in patients with NSCLC receiving targeted therapy; n=98 in patients with NSCLC without targetable mutations.

b

At 24 weeks, n=30 in patients with NSCLC receiving targeted therapy; n=75 in patients with NSCLC without targetable mutations.